T1	Parsing_Error 0 2	1.
T2	Parsing_Error 972 974	2.
T3	Parsing_Error 1032 1034	3.
T4	Parsing_Error 1166 1168	4.
T5	Parsing_Error 1503 1505	5.
T6	Parsing_Error 1542 1544	6.
T7	Measurement 1833 1843	Hemoglobin
T8	Value 1845 1853	≥ 9 g/dL
R1	Has_value Arg1:T7 Arg2:T8	
T9	Value 1873 1886	≥ 1.5 x 109/L
T10	Measurement 1855 1871	Neutrophil count
R2	Has_value Arg1:T10 Arg2:T9	
T11	Value 1904 1917	≥ 100,000/mm3
T12	Measurement 1888 1902	Platelet count
R3	Has_value Arg1:T12 Arg2:T11	
T13	Measurement 1919 1935	Serum creatinine
T14	Value 1937 1985	≤ 1.5x Institutional Upper Limit of Normal (ULN)
R4	Has_value Arg1:T13 Arg2:T14	
T15	Measurement 1990 2010	Creatinine Clearance
T16	Value 2011 2022	≥ 50 mL/min
R5	Has_value Arg1:T15 Arg2:T16	
T17	Qualifier 2027 2050	Cockcroft-Gault formula
R6	Has_qualifier Arg1:T15 Arg2:T17	
T18	Measurement 2053 2068	Serum bilirubin
T19	Value 2070 2081	≤ 1.2 mg/dL
R7	Has_value Arg1:T18 Arg2:T19	
T20	Condition 104 132	primary peritoneal carcinoma
T21	Condition 123 132;85 99	carcinoma fallopian tube
T22	Condition 123 132;65 83	carcinoma epithelial ovarian
T23	Qualifier 22 31	recurrent
T24	Qualifier 35 45	persistent
T25	Qualifier 46 64	platinum-resistant
*	OR T24 T23
*	OR T22 T21 T20
T27	Scope 65 132	epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
T26	Scope 22 45	recurrent or persistent
R8	Has_scope Arg1:T27 Arg2:T26	
R9	Has_qualifier Arg1:T27 Arg2:T25	
T28	Condition 138 157	measureable disease
T29	Temporal 186 197;208 240	after first line platinum-based chemotherapy
T30	Reference_point 192 197;208 240	first line platinum-based chemotherapy
T31	Temporal 186 191;201 240	after second line platinum-based chemotherapy
T32	Reference_point 201 240	second line platinum-based chemotherapy
R10	Has_index Arg1:T29 Arg2:T30	
R11	Has_index Arg1:T31 Arg2:T32	
*	OR T29 T31
T33	Scope 186 240	after first or second line platinum-based chemotherapy
R12	Has_scope Arg1:T28 Arg2:T33	
R13	AND Arg1:T27 Arg2:T28	
T34	Procedure 252 270	treatment with PLD
T35	Drug 267 270	PLD
T36	Qualifier 274 283	indicated
R14	Has_qualifier Arg1:T34 Arg2:T36	
T37	Undefined_semantics 274 283	indicated
T38	Subjective_judgement 274 283	indicated
R15	AND Arg1:T27 Arg2:T34	
T39	Procedure 285 307	Platinum-based therapy
T40	Drug 337 348	carboplatin
T41	Drug 350 359	cisplatin
T42	Drug 363 394	another organoplatinum compound
T43	Not_a_criteria 285 395	Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound.
*	OR T40 T41 T42
T44	Scope 337 394	carboplatin, cisplatin or another organoplatinum compound
R16	Subsumes Arg1:T39 Arg2:T44	
T45	Measurement 438 466	platinum-free interval (PFI)
T46	Temporal 470 537	< 12 months after first- or second-line platinum-based chemotherapy
T47	Reference_point 488 537	first- or second-line platinum-based chemotherapy
R17	Has_index Arg1:T46 Arg2:T47	
R18	Has_temporal Arg1:T45 Arg2:T46	
T48	Condition 396 414	Platinum-resistant
T49	Condition 549 568	disease progression
T50	Procedure 585 624	second-line platinum-based chemotherapy
T51	Scope 549 624	disease progression while receiving second-line platinum-based chemotherapy
*	OR T45 T51
T52	Scope 438 624	platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy
R19	Subsumes Arg1:T48 Arg2:T52	
T53	Parsing_Error 627 704	Subjects are allowed to have received, but are not required to have received:
T54	Drug 721 738	cytotoxic regimen
T55	Drug 746 760	PARP inhibitor
T56	Multiplier 706 720	one additional
*	OR T54 T55
T57	Scope 721 760	cytotoxic regimen and/or PARP inhibitor
R20	Has_multiplier Arg1:T57 Arg2:T56	
T58	Condition 803 810	disease
T59	Temporal 792 802	persistent
T60	Temporal 779 788	recurrent
*	OR T59 T60
T61	Scope 779 802	recurrent or persistent
R21	Has_scope Arg1:T58 Arg2:T61	
R22	AND Arg1:T57 Arg2:T58	
T62	Drug 837 848	bevacizumab
T63	Undefined_semantics 803 810	disease
T64	Procedure 813 829	biologic therapy
R23	Subsumes Arg1:T64 Arg2:T62	
T65	Procedure 867 892	primary treatment regimen
T66	Temporal 951 961	persistent
T67	Temporal 938 947	recurrent
*	OR T66 T67
T68	Scope 938 961	recurrent or persistent
T69	Condition 962 969	disease
R24	Has_scope Arg1:T69 Arg2:T68	
T70	Procedure 910 919	treatment
R25	AND Arg1:T70 Arg2:T69	
R26	Subsumes Arg1:T65 Arg2:T64	
R27	Subsumes Arg1:T65 Arg2:T70	
T71	Context_Error 938 969	recurrent or persistent disease
T72	Undefined_semantics 938 969	recurrent or persistent disease
T73	Procedure 975 985	Histologic
T74	Condition 1007 1029	original primary tumor
T75	Value 986 999	documentation
R28	Has_value Arg1:T73 Arg2:T75	
R29	AND Arg1:T74 Arg2:T73	
T76	Procedure 1046 1058	radiographic
T77	Condition 1059 1078	disease progression
R30	AND Arg1:T76 Arg2:T77	
T78	Temporal 1079 1163	< 12 months after the last dose of first- or second-line platinum-based chemotherapy
T79	Reference_point 1097 1163	the last dose of first- or second-line platinum-based chemotherapy
R31	Has_index Arg1:T78 Arg2:T79	
R32	Has_temporal Arg1:T77 Arg2:T78	
T80	Condition 1199 1225	disease amenable to biopsy
T81	Subjective_judgement 1199 1225	disease amenable to biopsy
T82	Undefined_semantics 1199 1225	disease amenable to biopsy
T83	Non-query-able 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
T84	Post-eligibility 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
T85	Parsing_Error 1297 1318	Optional for Phase 1.
T86	Not_a_criteria 1320 1501	Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry.
T87	Measurement 1506 1529	ECOG performance status
T88	Value 1533 1539	0 or 1
R33	Has_value Arg1:T87 Arg2:T88	
T89	Measurement 1545 1586	Laboratory parameters for vital functions
T90	Undefined_semantics 1545 1586	Laboratory parameters for vital functions
T91	Value 1604 1616	normal range
R34	Has_value Arg1:T89 Arg2:T91	
T92	Measurement 2083 2090	AST/ALT
T93	Value 2092 2103	≤ 2.5 x ULN
R35	Has_value Arg1:T92 Arg2:T93	
T94	Measurement 2105 2125	Alkaline phosphatase
T95	Value 2127 2138	≤ 2.5 x ULN
R36	Has_value Arg1:T94 Arg2:T95	
T96	Parsing_Error 2140 2142	7.
T97	Person 2143 2146	Age
T98	Value 2147 2156	≥18 years
R37	Has_value Arg1:T97 Arg2:T98	
T99	Parsing_Error 2159 2161	8.
T100	Non-query-able 2162 2218	Able and willing to give valid written informed consent.
T101	Post-eligibility 2162 2218	Able and willing to give valid written informed consent.
T102	Parsing_Error 2220 2222	9.
T103	Measurement 2223 2234	Body weight
T104	Value 2235 2242	> 30 kg
R38	Has_value Arg1:T103 Arg2:T104	
